Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Debt: 2014-2025

Historic Total Debt for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $316.1 million.

  • ImmunityBio's Total Debt rose 15.53% to $316.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.1 million, marking a year-over-year increase of 15.53%. This contributed to the annual value of $284.4 million for FY2024, which is 83.00% up from last year.
  • Latest data reveals that ImmunityBio reported Total Debt of $316.1 million as of Q3 2025, which was up 2.96% from $307.0 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Total Debt peaked at $480.0 million during Q3 2023, and registered a low of $155.4 million during Q4 2023.
  • In the last 3 years, ImmunityBio's Total Debt had a median value of $279.0 million in 2024 and averaged $278.5 million.
  • Its Total Debt has fluctuated over the past 5 years, first surged by 36,840.56% in 2021, then tumbled by 42.99% in 2024.
  • Over the past 5 years, ImmunityBio's Total Debt (Quarterly) stood at $306.3 million in 2021, then grew by 19.67% to $373.3 million in 2022, then climbed by 28.59% to $155.4 million in 2023, then skyrocketed by 83.00% to $284.4 million in 2024, then rose by 15.53% to $316.1 million in 2025.
  • Its Total Debt was $316.1 million in Q3 2025, compared to $307.0 million in Q2 2025 and $296.3 million in Q1 2025.